Final diagnoses were as follows: ischemic stroke, n = 258
5 About the SELECT Trial SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a multicenter, randomized, double-blind, placebo-controlled, event-driven superiority trial designed to evaluate the efficacy of Wegovy 2.4 mg versus placebo as an adjunct to cardiovascular standard of care for reducing the risk of major adverse cardiovascular events in people with established CVD with overweight or obesity with no prior history of diabetes
Higher lifetime treatment costs are consistently accompanied by greater expected life expectancies and quality of life for treatment pathways initiated with semaglutide
Because it is tied to insulin-like growth factor activity, it may affect blood sugar, tissue growth signaling, water retention, swelling, and other body systems
It contains the same active ingredient as Ozempic and Wegovy, which is my recommended approach for taking GLP-1 internally for weight loss results, but with continuous medical guidance
acta como antioxidante protegiendo a las clulas del dao oxidativo y aumenta la produccin de xido ntrico (NO), con lo que aumenta la potencia muscular en series submximas de repetidas de entrenamiento
